akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Monday, August 10, 2015

Company News: Merus Prevails in Inequitable Conduct Case Against Regeneron

- Court ruling further strengthens Merus’ freedom to operate in using transgenic mice for therapeutic human antibodies

Merus, a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that it won its inequitable conduct trial against Regeneron. In a decision issued on Thursday, August 6, Judge Katherine B. Forrest of the U.S. District Court for the Southern District of New York indicated that Regeneron engaged in inequitable conduct in connection with obtaining U.S. Patent No. 8,502,018. This marks the third counterclaim upon which Merus has prevailed in this litigation, initiated by Regeneron. In December 2014, Regeneron conceded that Merus does not infringe any claim of the ‘018 patent, and that the patent is invalid in view of the Court’s prior decision on claim construction. Given the Court’s ruling on August 6, Regeneron’s patent has now been adjudged to be not infringed, invalid and unenforceable for being procured by inequitable conduct.

Tuesday, July 28, 2015

Company News: PNAS Paper Details Efficacy of a Potent, Fully Human Antibody for the Treatment of MERS

- First human-derived antibody which is suitable for prophylaxis, post-exposure prophylaxis, and treatment of MERS

- Therapeutic compound under development by Humabs BioMed on a non-profit basis

Humabs BioMed SA, a leading Swiss antibody therapeutics company, today announced that Proceedings of the National Academy of Sciences (PNAS) has published a paper describing the isolation and characterization of a potent antibody from memory B-cells of a patient recovering from an infection with coronavirus (CoV) and the resulting Middle East Respiratory Syndrome (MERS). The antibody, which was isolated from the infected individual two years ago, is active against all three clinically relevant MERS-CoV strains and against a site that is conserved in all MERS strains, including the strain responsible for the latest outbreak in South Korea. Humabs has developed a production cell line allowing  – depending on regulatory clearance – the antibody either to be made available on the basis of a compassionate use program or to enter Phase I trials within a few months.